Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

BACKGROUND: We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700279/
https://www.ncbi.nlm.nih.gov/pubmed/34953520
http://dx.doi.org/10.1016/S1473-3099(21)00751-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700279/
https://www.ncbi.nlm.nih.gov/pubmed/34953520
http://dx.doi.org/10.1016/S1473-3099(21)00751-9

Ejemplares similares